EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations

Gautam U Mehta iD, Paz J Vellanki, Yi Ren, Anup K Amatya, Pallavi S Mishra-Kalyani, Lili Pan, Jeanne F Zirkelbach, Yuzhuo Pan, Jiang Liu, Stephanie L Aungst, Claudia P Miller, Mirat Shah und 6 weitere

The Oncologist · 05.08.2024 · 29 (8) · 667-671

DOI: 10.1093/oncolo/oyae151 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Oncologist, online erschienen am 06.07.2024. Verfasst von Gautam U Mehta und 17 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, United States. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Erb-b2 Receptor Tyrosine Kinases, Lung Neoplasms, Trastuzumab. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

On August 11, 2022, FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (DS-8201a, T-DXd, ENHERTU, Daiichi Sankyo) for adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating human epidermal growth factor receptor 2 (HER2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy. The approval was based on a prespecified interim analysis of DESTINY-Lung02 (Study U206), a multi-center, randomized, dose-optimization trial in patients with NSCLC harboring activating HER2-mutations. At the approved dose of 5.4 mg/kg given intravenously every 3 weeks, the overall response rate (ORR) was 58% (95% confidence interval [CI]: 43, 71). The median duration of response was 8.7 months (95% CI: 7.1, not estimable). These results were consistent with response rates observed at the 6.4 mg/kg dose level. The most common (≥ 20%) adverse reactions were nausea, constipation, decreased appetite, vomiting, fatigue, and alopecia. The rate of interstitial lung disease (ILD) or pneumonitis was 6% at the 5.4 mg/kg dose level and 14% at the 6.4 mg/kg dose level. In the setting of similar efficacy and reduced toxicity, approval was granted for the 5.4 mg/kg dose level. The applicant conducted a randomized, dose-optimization study with guidance from the FDA Oncology Center of Excellence’s Project Optimus. This is the first approval of a targeted therapy for HER2-mutated NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungErb-b2 Receptor Tyrosine KinasesLung NeoplasmsTrastuzumabMutationHumansFemaleMaleMiddle AgedUnited StatesUnited States Food and Drug AdministrationDrug ApprovalAgedImmunoconjugatesCamptothecinAdultAntibodies, Monoclonal, Humanized

Substanzen

Erb-b2 Receptor Tyrosine KinasesTrastuzumabImmunoconjugatesCamptothecinAntibodies, Monoclonal, Humanizedtrastuzumab deruxtecanERBB2 protein, human

Autor:innen und Institutionen

  • Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, United States.
  • Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD, United States.

ORCID-Profile: Gautam U Mehta

Zitieren

APA

Mehta, G. U., Vellanki, P. J., Ren, Y., Amatya, A. K., Mishra-Kalyani, P. S., Pan, L., Zirkelbach, J. F., Pan, Y., Liu, J., Aungst, S. L., Miller, C. P., Shah, M., Rahman, N. A., Theoret, M., Kluetz, P., Pazdur, R., Beaver, J. A., & Singh, H. (2024). FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations. The Oncologist, 29(8), 667-671. https://doi.org/10.1093/oncolo/oyae151

Vancouver

Mehta GU, Vellanki PJ, Ren Y, Amatya AK, Mishra-Kalyani PS, Pan L, et al. FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations. The Oncologist. 2024;29(8):667-671. doi:10.1093/oncolo/oyae151

BibTeX
@article{Mehta2024,
  author = {Mehta, Gautam U and Vellanki, Paz J and Ren, Yi and Amatya, Anup K and Mishra-Kalyani, Pallavi S and Pan, Lili and Zirkelbach, Jeanne F and Pan, Yuzhuo and Liu, Jiang and Aungst, Stephanie L and Miller, Claudia P and Shah, Mirat and Rahman, Nam Atiqur and Theoret, Marc and Kluetz, Paul and Pazdur, Richard and Beaver, Julia A and Singh, Harpreet},
  title = {FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations},
  journal = {The Oncologist},
  year = {2024},
  volume = {29},
  number = {8},
  pages = {667--671},
  doi = {10.1093/oncolo/oyae151}
}
Kostenlos starten →